AIM
MYGN icon

Assured Investment Management’s Myriad Genetics MYGN Stock Holding History

Assured Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200,000
Closed -$7.78M – 260
2014
Q2 		$7.78M Hold
200,000
– – 0.13% 122
2014
Q1 		$6.84M Buy
+200,000
New +$6.2M 0.11% 144

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Assured Investment Management's MYGN Position: Q4 2018 in Review

Assured Investment Management sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 2,133 shares — an estimated $98K sold.

Assured Investment Management first reported a position in MYGN in Q3 2013 and held it in 10 quarters. The position peaked at $28.8M in Q1 2014. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • Assured Investment Management reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • Assured Investment Management sold 2,133 Myriad Genetics shares in Q4 2018, an estimated $98K.
  • Assured Investment Management first reported a position in Myriad Genetics in Q3 2013 and held it in 10 quarters.
  • Assured Investment Management's Myriad Genetics position peaked at $28.8M in Q1 2014.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Assured Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.